CFTR: cystic fibrosis and beyond
Cystic fibrosis (CF) remains the most common fatal hereditary lung disease. The discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene 25 years ago set the stage for: 1) unravelling the molecular and cellular basis of CF lung disease; 2) the generation of animal models to s...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
June 12, 2014
|
| In: |
The European respiratory journal
Year: 2014, Jahrgang: 44, Heft: 4, Pages: 1042-1054 |
| ISSN: | 1399-3003 |
| DOI: | 10.1183/09031936.00228013 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1183/09031936.00228013 Verlag, lizenzpflichtig, Volltext: https://erj.ersjournals.com/content/44/4/1042 
|
| Verfasserangaben: | Marcus A. Mall and Dominik Hartl |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1725228920 | ||
| 003 | DE-627 | ||
| 005 | 20230426183659.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200721s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1183/09031936.00228013 |2 doi | |
| 035 | |a (DE-627)1725228920 | ||
| 035 | |a (DE-599)KXP1725228920 | ||
| 035 | |a (OCoLC)1341347016 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Mall, Marcus A. |d 1975- |e VerfasserIn |0 (DE-588)115507795 |0 (DE-627)691370532 |0 (DE-576)28992152X |4 aut | |
| 245 | 1 | 0 | |a CFTR |b cystic fibrosis and beyond |c Marcus A. Mall and Dominik Hartl |
| 264 | 1 | |c June 12, 2014 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 21.07.2020 | ||
| 520 | |a Cystic fibrosis (CF) remains the most common fatal hereditary lung disease. The discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene 25 years ago set the stage for: 1) unravelling the molecular and cellular basis of CF lung disease; 2) the generation of animal models to study in vivo pathogenesis; and 3) the development of mutation-specific therapies that are now becoming available for a subgroup of patients with CF. This article highlights major advances in our understanding of how CFTR dysfunction causes chronic mucus obstruction, neutrophilic inflammation and bacterial infection in CF airways. Furthermore, we focus on recent breakthroughs and remaining challenges of novel therapies targeting the basic CF defect, and discuss the next steps to be taken to make disease-modifying therapies available to a larger group of patients with CF, including those carrying the most common mutation ΔF508-CFTR. Finally, we will summarise emerging evidence indicating that acquired CFTR dysfunction may be implicated in the pathogenesis of chronic obstructive pulmonary disease, suggesting that lessons learned from CF may be applicable to common airway diseases associated with mucus plugging. - Tweetable abstract ERSpublications - click to tweetCFTR dysfunction causes CF and may be implicated in more common chronic obstructive lung diseases, such as COPD http://ow.ly/wplhu | ||
| 700 | 1 | |a Hartl, Dominik |d 1977- |e VerfasserIn |0 (DE-588)128642211 |0 (DE-627)376944382 |0 (DE-576)29725572X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The European respiratory journal |d Lausanne : ERS, 1988 |g 44(2014), 4, Seite 1042-1054 |h Online-Ressource |w (DE-627)306646803 |w (DE-600)1499101-9 |w (DE-576)091142504 |x 1399-3003 |7 nnas |a CFTR cystic fibrosis and beyond |
| 773 | 1 | 8 | |g volume:44 |g year:2014 |g number:4 |g pages:1042-1054 |g extent:13 |a CFTR cystic fibrosis and beyond |
| 856 | 4 | 0 | |u https://doi.org/10.1183/09031936.00228013 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://erj.ersjournals.com/content/44/4/1042 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200721 | ||
| 993 | |a Article | ||
| 994 | |a 2014 | ||
| 998 | |g 115507795 |a Mall, Marcus A. |m 115507795:Mall, Marcus A. |d 910000 |d 910500 |e 910000PM115507795 |e 910500PM115507795 |k 0/910000/ |k 1/910000/910500/ |p 1 |x j | ||
| 999 | |a KXP-PPN1725228920 |e 372700097X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"13 S."}],"relHost":[{"corporate":[{"roleDisplay":"Herausgebendes Organ","display":"European Respiratory Society","role":"isb"}],"language":["eng"],"recId":"306646803","disp":"CFTR cystic fibrosis and beyondThe European respiratory journal","type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 25.04.2025","Fortsetzung der Druck-Ausgabe"],"titleAlt":[{"title":"official journal of the European Society for Clinical Respiratory Physiology : ERJ"},{"title":"ERJ"}],"part":{"issue":"4","pages":"1042-1054","year":"2014","extent":"13","text":"44(2014), 4, Seite 1042-1054","volume":"44"},"pubHistory":["1.1988 -"],"title":[{"title_sort":"European respiratory journal","title":"The European respiratory journal","subtitle":"flagship scientific journal of ERS"}],"physDesc":[{"extent":"Online-Ressource"}],"name":{"displayForm":["European Respiratory Society"]},"id":{"eki":["306646803"],"zdb":["1499101-9"],"issn":["1399-3003"]},"origin":[{"publisherPlace":"Lausanne ; Copenhagen","dateIssuedKey":"1988","publisher":"ERS ; Munksgaard","dateIssuedDisp":"1988-"}]}],"name":{"displayForm":["Marcus A. Mall and Dominik Hartl"]},"origin":[{"dateIssuedDisp":"June 12, 2014","dateIssuedKey":"2014"}],"id":{"doi":["10.1183/09031936.00228013"],"eki":["1725228920"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 21.07.2020"],"language":["eng"],"recId":"1725228920","person":[{"family":"Mall","given":"Marcus A.","roleDisplay":"VerfasserIn","display":"Mall, Marcus A.","role":"aut"},{"role":"aut","display":"Hartl, Dominik","roleDisplay":"VerfasserIn","given":"Dominik","family":"Hartl"}],"title":[{"title":"CFTR","subtitle":"cystic fibrosis and beyond","title_sort":"CFTR"}]} | ||
| SRT | |a MALLMARCUSCFTR1220 | ||